259 related articles for article (PubMed ID: 22155903)
1. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection.
Marais D; Gawarecki D; Allan B; Ahmed K; Altini L; Cassim N; Gopolang F; Hoffman M; Ramjee G; Williamson AL
Antivir Ther; 2011; 16(8):1219-26. PubMed ID: 22155903
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand.
Kilmarx PH; Blanchard K; Chaikummao S; Friedland BA; Srivirojana N; Connolly C; Witwatwongwana P; Supawitkul S; Mock PA; Chaowanachan T; Tappero J
Sex Transm Dis; 2008 Mar; 35(3):226-32. PubMed ID: 18490865
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.
Skoler-Karpoff S; Ramjee G; Ahmed K; Altini L; Plagianos MG; Friedland B; Govender S; De Kock A; Cassim N; Palanee T; Dozier G; Maguire R; Lahteenmaki P
Lancet; 2008 Dec; 372(9654):1977-87. PubMed ID: 19059048
[TBL] [Abstract][Full Text] [Related]
4. Acceptability of Carraguard vaginal gel use among Thai couples.
Whitehead SJ; Kilmarx PH; Blanchard K; Manopaiboon C; Chaikummao S; Friedland B; Achalapong J; Wankrairoj M; Mock P; Thanprasertsuk S; Tappero JW
AIDS; 2006 Nov; 20(17):2141-8. PubMed ID: 17086053
[TBL] [Abstract][Full Text] [Related]
5. Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial.
Friedland BA; Stoner M; Chau MM; Plagianos MG; Govender S; Morar N; Altini L; Skoler-Karpoff S; Ahmed K; Ramjee G; Monedi C; Maguire R; Lähteenmäki P
AIDS Behav; 2016 Nov; 20(11):2565-2577. PubMed ID: 26204987
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study.
Iftner T; Eberle S; Iftner A; Holz B; Banik N; Quint W; Straube AN
J Med Virol; 2010 Nov; 82(11):1928-39. PubMed ID: 20872721
[TBL] [Abstract][Full Text] [Related]
7. Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women.
Nielsen A; Kjaer SK; Munk C; Iftner T
Sex Transm Dis; 2008 Mar; 35(3):276-82. PubMed ID: 18091564
[TBL] [Abstract][Full Text] [Related]
8. Impact of a new carrageenan-based vaginal microbicide in a female population with genital HPV-infection: first experimental results.
Perino A; Consiglio P; Maranto M; De Franciscis P; Marci R; Restivo V; Manzone M; Capra G; Cucinella G; Calagna G
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6744-6752. PubMed ID: 31378918
[TBL] [Abstract][Full Text] [Related]
9. HIV genital shedding and safety of Carraguard use by HIV-infected women: a crossover trial in Thailand.
McLean CA; van de Wijgert JH; Jones HE; Karon JM; McNicoll JM; Whitehead SJ; Braunstein S; Achalapong J; Chaikummao S; Tappero JW; Markowitz LE; Kilmarx PH
AIDS; 2010 Mar; 24(5):717-22. PubMed ID: 20098295
[TBL] [Abstract][Full Text] [Related]
10. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group.
Hankins C; Coutlée F; Lapointe N; Simard P; Tran T; Samson J; Hum L
CMAJ; 1999 Jan; 160(2):185-91. PubMed ID: 9951439
[TBL] [Abstract][Full Text] [Related]
12. Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand.
Whitehead SJ; McLean C; Chaikummao S; Braunstein S; Utaivoravit W; van de Wijgert JH; Mock PA; Siraprapasiri T; Friedland BA; Kilmarx PH; Markowitz LE
PLoS One; 2011; 6(9):e14831. PubMed ID: 21915249
[TBL] [Abstract][Full Text] [Related]
13. Effect of Replens gel used with a diaphragm on tests for human papillomavirus and other lower genital tract infections.
Smith-McCune KK; Tuveson JL; Rubin MM; Da Costa MM; Darragh TM; Shiboski SC; Van Der Pol B; Moscicki AB; Palefsky JM; Sawaya GF
J Low Genit Tract Dis; 2006 Oct; 10(4):213-8. PubMed ID: 17012985
[TBL] [Abstract][Full Text] [Related]
14. Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa.
van de Wijgert JH; Braunstein SL; Morar NS; Jones HE; Madurai L; Strickfaden TT; Moodley M; Aboobaker J; Ndlovu G; Ferguson TM; Friedland BA; Hart CE; Ramjee G
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):538-46. PubMed ID: 18193495
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and risk factors for human papillomavirus DNA in cervical cytology.
Kasap B; Yetimalar H; Keklik A; Yildiz A; Cukurova K; Soylu F
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):168-71. PubMed ID: 21764503
[TBL] [Abstract][Full Text] [Related]
16. Expanded safety and acceptability of the candidate vaginal microbicide Carraguard® in South Africa.
Carraguard Phase II South Africa Study Team
Contraception; 2010 Dec; 82(6):563-71. PubMed ID: 21074021
[TBL] [Abstract][Full Text] [Related]
17. Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.
van de Wijgert JH; Kilmarx PH; Jones HE; Karon JM; Chaikummao S
Contraception; 2008 Feb; 77(2):122-9. PubMed ID: 18226677
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for high-risk human papillomavirus detection among HIV-negative and HIV-positive women from Tanzania.
Dartell M; Rasch V; Munk C; Kahesa C; Mwaiselage J; Iftner T; Kjaer SK
Sex Transm Dis; 2013 Sep; 40(9):737-43. PubMed ID: 23949589
[TBL] [Abstract][Full Text] [Related]
19. Anal human papillomavirus DNA screening by Hybrid Capture II in human immunodeficiency virus-positive patients with or without anal intercourse.
Drobacheff C; Dupont P; Mougin C; Bourezane Y; Challier B; Fantoli M; Bettinger D; Laurent R
Eur J Dermatol; 2003; 13(4):367-71. PubMed ID: 12948917
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up.
Branca M; Garbuglia AR; Benedetto A; Cappiello T; Leoncini L; Migliore G; Agarossi A; Syrjänen K;
Int J STD AIDS; 2003 Jun; 14(6):417-25. PubMed ID: 12816671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
